• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by NanoVibronix Inc.

    6/25/25 4:05:18 PM ET
    $NAOV
    Industrial Specialties
    Health Care
    Get the next $NAOV alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.    )

     

    Filed by the Registrant  ☒
    Filed by a Party other than the Registrant  ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the SEC Only (As Permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to § 240.14a-12

     

    NanoVibronix, Inc.

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required.
    ☐ Fee paid previously with preliminary materials.
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

    SUPPLEMENT TO DEFINITIVE PROXY STATEMENT

    FOR THE SPECIAL MEETING OF STOCKHOLDERS

    TO BE HELD ON JULY 11, 2025

     

    EXPLANATORY NOTE

     

    On June 20, 2025, NanoVibronix, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement on Schedule 14A (the “Proxy Statement”) relating to the Company’s Special Meeting of Stockholders (the “Special Meeting”) to be held on Friday, July 11, 2025, commencing at 10:00 a.m., Eastern Time. As previously disclosed, the board of directors of the Company has fixed the close of business on May 16, 2025, as the record date (the “Record Date”) for determining stockholders entitled to vote at the Special Meeting and at any adjournment(s) or postponement(s) thereof. Capitalized terms used in this supplement to the Proxy Statement (this “Supplement”) without definition have the same meanings as set forth in the Proxy Statement.

     

    This Supplement is being filed to correct an inadvertent error in the number of shares of preferred stock reported as outstanding as of the Record Date on page 3 of the Proxy Statement. On page 3 thereof, the Proxy Statement previously stated that there were no shares of any series of preferred stock outstanding, when there were 320,348 shares of Series G Preferred Stock and 57,720 shares of Series X Preferred Stock of the Company issued and outstanding as of the Record Date. This change solely affects the disclosure as related to such shares of preferred stock outstanding as of the Record Date as reported on page 3 of the Proxy Statement.

      

    This Supplement should be read in conjunction with the Proxy Statement. Except as specifically amended or supplemented by the information contained herein, this Supplement does not otherwise modify, amend or supplement the Proxy Statement, and the information contained in the Proxy Statement should be considered in voting your shares. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Proxy Statement as supplemented hereby.

     

    If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote.

     

    ***

     

    The following text replaces, in its entirety, the text on page 3 of the Proxy Statement appearing below “Who is entitled to vote at the Special Meeting and how many votes do they have?”

     

    Holders of Common Stock at the close of business on the Record Date, may vote at the Special Meeting. There were 2,282,746 shares of Common Stock, 0 shares of Series C Preferred Stock, 0 shares of Series D Preferred Stock, 0 shares of Series E Preferred Stock, 0 shares of Series F Preferred Stock, 320,348 shares of Series G Preferred Stock and 57,720 shares of Series X Preferred Stock issued and outstanding on the Record Date. A complete list of registered stockholders entitled to vote at the Special Meeting will be available for inspection at the principal executive offices of the Company during regular business hours for the 10 calendar days prior to the Special Meeting.

     

    Pursuant to the rights of our stockholders contained in our charter documents, each share of our Common Stock is entitled to one vote on all matters listed in this proxy statement. There is no cumulative voting. 

     

     

     

    Get the next $NAOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe Line

    TYLER, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the signing of a distribution agreement with U-Deliver to distribute ENvue's recently launched over-the-counter reusable ENFit Syringes product line nationwide through non-acute care channels. "We believe that our partnership with U-Deliver is an important step in scaling ENvue's over-the-counter ENFit syringe line and strengthening our presence in the non-acute enteral care marke

    1/28/26 9:00:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical Launches Over-the-Counter Reusable ENFit Syringes to Support Feeding and Medication Delivery without a Prescription

    TYLER, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a line of over-the-counter ENFit Syringes designed to meet both feeding and medication delivery clinical needs. "As care continues to shift beyond the hospital setting, providers and caregivers need reliable, high-quality solutions that support patients throughout the entire care journey," said Doron Besser, MD, CEO of ENvue Medical. "With the launch of our over-the-

    1/14/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    SEC Filings

    View All

    SEC Form 424B3 filed by NanoVibronix Inc.

    424B3 - ENvue Medical, Inc. (0001326706) (Filer)

    12/18/25 5:00:19 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NanoVibronix, Inc. (0001326706) (Filer)

    12/12/25 9:06:28 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form S-3/A filed by NanoVibronix Inc.

    S-3/A - NanoVibronix, Inc. (0001326706) (Filer)

    12/9/25 9:28:07 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Pionati Pellegrino

    3 - ENvue Medical, Inc. (0001326706) (Issuer)

    12/18/25 5:40:32 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Johnson David Ian

    3 - ENvue Medical, Inc. (0001326706) (Issuer)

    12/18/25 5:36:25 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Executive Officer Murphy Brian M

    4 - NanoVibronix, Inc. (0001326706) (Issuer)

    1/3/25 4:05:16 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Announces CEO Transition

    NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

    6/4/25 8:38:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

    NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on

    12/15/22 4:05:00 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Financials

    Live finance-specific insights

    View All

    NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

    NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh

    9/14/22 9:25:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by NanoVibronix Inc.

    SC 13G - NanoVibronix, Inc. (0001326706) (Subject)

    2/14/24 3:45:41 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    2/16/21 3:49:24 PM ET
    $NAOV
    Industrial Specialties
    Health Care